BiondVax rounds up $9.5M in IPO

BiondVax ($BVXV) raised $9.5 million in a Nasdaq IPO, pricing 1,910,000 shares at $5.01 each. The Israel-based company is working on a universal flu vaccine to protect against all strains of the virus, including seasonal strains and pandemics. CEO Ron Babecoff said the funds will allow BiondVax to "promote its clinical activities and speed it up while developing business-wise," Globes reported. More

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.